Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.23
HRT's Cash to Debt is ranked lower than
87% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.56 vs. HRT: 0.23 )
Ranked among companies with meaningful Cash to Debt only.
HRT' s 10-Year Cash to Debt Range
Min: 0.04  Med: 3.41 Max: No Debt
Current: 0.23
Equity to Asset 0.47
HRT's Equity to Asset is ranked lower than
74% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 0.66 vs. HRT: 0.47 )
Ranked among companies with meaningful Equity to Asset only.
HRT' s 10-Year Equity to Asset Range
Min: 0.39  Med: 0.86 Max: 0.96
Current: 0.47
0.39
0.96
Interest Coverage 3.25
HRT's Interest Coverage is ranked lower than
94% of the 166 Companies
in the Global Medical Devices industry.

( Industry Median: 10000.00 vs. HRT: 3.25 )
Ranked among companies with meaningful Interest Coverage only.
HRT' s 10-Year Interest Coverage Range
Min: 1.81  Med: 13.91 Max: 9999.99
Current: 3.25
1.81
9999.99
F-Score: 7
Z-Score: 2.91
M-Score: -2.68
WACC vs ROIC
1.19%
3.29%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 1.51
HRT's Operating margin (%) is ranked lower than
52% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 3.12 vs. HRT: 1.51 )
Ranked among companies with meaningful Operating margin (%) only.
HRT' s 10-Year Operating margin (%) Range
Min: -15.6  Med: 5.18 Max: 21.71
Current: 1.51
-15.6
21.71
Net-margin (%) 2.13
HRT's Net-margin (%) is ranked higher than
51% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.99 vs. HRT: 2.13 )
Ranked among companies with meaningful Net-margin (%) only.
HRT' s 10-Year Net-margin (%) Range
Min: -29.73  Med: 3.09 Max: 16.4
Current: 2.13
-29.73
16.4
ROE (%) 7.24
HRT's ROE (%) is ranked higher than
60% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 3.14 vs. HRT: 7.24 )
Ranked among companies with meaningful ROE (%) only.
HRT' s 10-Year ROE (%) Range
Min: -48.14  Med: 6.33 Max: 16.68
Current: 7.24
-48.14
16.68
ROA (%) 3.24
HRT's ROA (%) is ranked higher than
59% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: -0.33 vs. HRT: 3.24 )
Ranked among companies with meaningful ROA (%) only.
HRT' s 10-Year ROA (%) Range
Min: -33.69  Med: 4.25 Max: 15.41
Current: 3.24
-33.69
15.41
ROC (Joel Greenblatt) (%) 3.87
HRT's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. HRT: 3.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HRT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -31.98  Med: 9.40 Max: 41.67
Current: 3.87
-31.98
41.67
Revenue Growth (3Y)(%) -1.20
HRT's Revenue Growth (3Y)(%) is ranked lower than
62% of the 194 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. HRT: -1.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HRT' s 10-Year Revenue Growth (3Y)(%) Range
Min: -25.3  Med: 1.70 Max: 34.6
Current: -1.2
-25.3
34.6
EBITDA Growth (3Y)(%) -2.20
HRT's EBITDA Growth (3Y)(%) is ranked lower than
55% of the 173 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. HRT: -2.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
HRT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -35.3  Med: -2.15 Max: 39.9
Current: -2.2
-35.3
39.9
EPS Growth (3Y)(%) -5.20
HRT's EPS Growth (3Y)(%) is ranked lower than
55% of the 173 Companies
in the Global Medical Devices industry.

( Industry Median: -0.40 vs. HRT: -5.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
HRT' s 10-Year EPS Growth (3Y)(%) Range
Min: -44.1  Med: 18.60 Max: 162.1
Current: -5.2
-44.1
162.1
» HRT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

HRT Guru Trades in Q2 2014

Jim Simons 65,900 sh (+10.57%)
» More
Q3 2014

HRT Guru Trades in Q3 2014

Jim Simons 74,300 sh (+12.75%)
» More
Q4 2014

HRT Guru Trades in Q4 2014

Jim Simons 83,400 sh (+12.25%)
» More
Q1 2015

HRT Guru Trades in Q1 2015

Jim Simons 87,600 sh (+5.04%)
» More
» Details

Insider Trades

Latest Guru Trades with HRT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 33.40
HRT's P/E(ttm) is ranked lower than
61% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 27.60 vs. HRT: 33.40 )
Ranked among companies with meaningful P/E(ttm) only.
HRT' s 10-Year P/E(ttm) Range
Min: 9.74  Med: 24.65 Max: 54.67
Current: 33.4
9.74
54.67
PE(NRI) 106.30
HRT's PE(NRI) is ranked lower than
90% of the 154 Companies
in the Global Medical Devices industry.

( Industry Median: 27.80 vs. HRT: 106.30 )
Ranked among companies with meaningful PE(NRI) only.
HRT' s 10-Year PE(NRI) Range
Min: 9.55  Med: 25.71 Max: 398
Current: 106.3
9.55
398
P/B 2.43
HRT's P/B is ranked higher than
61% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 3.13 vs. HRT: 2.43 )
Ranked among companies with meaningful P/B only.
HRT' s 10-Year P/B Range
Min: 0.26  Med: 1.17 Max: 7.71
Current: 2.43
0.26
7.71
P/S 0.77
HRT's P/S is ranked higher than
86% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 3.19 vs. HRT: 0.77 )
Ranked among companies with meaningful P/S only.
HRT' s 10-Year P/S Range
Min: 0.2  Med: 0.72 Max: 7.61
Current: 0.77
0.2
7.61
PFCF 26.58
HRT's PFCF is ranked higher than
63% of the 116 Companies
in the Global Medical Devices industry.

( Industry Median: 31.45 vs. HRT: 26.58 )
Ranked among companies with meaningful PFCF only.
HRT' s 10-Year PFCF Range
Min: 3.14  Med: 31.07 Max: 901.63
Current: 26.58
3.14
901.63
POCF 8.86
HRT's POCF is ranked higher than
88% of the 149 Companies
in the Global Medical Devices industry.

( Industry Median: 21.48 vs. HRT: 8.86 )
Ranked among companies with meaningful POCF only.
HRT' s 10-Year POCF Range
Min: 1.76  Med: 12.33 Max: 43.45
Current: 8.86
1.76
43.45
EV-to-EBIT 50.75
HRT's EV-to-EBIT is ranked lower than
81% of the 163 Companies
in the Global Medical Devices industry.

( Industry Median: 22.11 vs. HRT: 50.75 )
Ranked among companies with meaningful EV-to-EBIT only.
HRT' s 10-Year EV-to-EBIT Range
Min: -181.6  Med: 14.10 Max: 554.5
Current: 50.75
-181.6
554.5
Current Ratio 1.22
HRT's Current Ratio is ranked lower than
86% of the 311 Companies
in the Global Medical Devices industry.

( Industry Median: 2.69 vs. HRT: 1.22 )
Ranked among companies with meaningful Current Ratio only.
HRT' s 10-Year Current Ratio Range
Min: 1.04  Med: 3.82 Max: 10.41
Current: 1.22
1.04
10.41
Quick Ratio 0.81
HRT's Quick Ratio is ranked lower than
85% of the 311 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. HRT: 0.81 )
Ranked among companies with meaningful Quick Ratio only.
HRT' s 10-Year Quick Ratio Range
Min: 0.63  Med: 2.67 Max: 8.09
Current: 0.81
0.63
8.09
Days Inventory 51.77
HRT's Days Inventory is ranked higher than
90% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 131.50 vs. HRT: 51.77 )
Ranked among companies with meaningful Days Inventory only.
HRT' s 10-Year Days Inventory Range
Min: 45.54  Med: 61.95 Max: 118.29
Current: 51.77
45.54
118.29
Days Sales Outstanding 61.24
HRT's Days Sales Outstanding is ranked higher than
62% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.21 vs. HRT: 61.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
HRT' s 10-Year Days Sales Outstanding Range
Min: 43.17  Med: 58.78 Max: 73.61
Current: 61.24
43.17
73.61

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 2.46
HRT's Price/Tangible Book is ranked higher than
72% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 4.53 vs. HRT: 2.46 )
Ranked among companies with meaningful Price/Tangible Book only.
HRT' s 10-Year Price/Tangible Book Range
Min: 0.38  Med: 1.20 Max: 10.73
Current: 2.46
0.38
10.73
Price/Median PS Value 1.08
HRT's Price/Median PS Value is ranked higher than
53% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 1.13 vs. HRT: 1.08 )
Ranked among companies with meaningful Price/Median PS Value only.
HRT' s 10-Year Price/Median PS Value Range
Min: 0.34  Med: 0.99 Max: 15.26
Current: 1.08
0.34
15.26
Price/Graham Number 1.95
HRT's Price/Graham Number is ranked higher than
59% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. HRT: 1.95 )
Ranked among companies with meaningful Price/Graham Number only.
HRT' s 10-Year Price/Graham Number Range
Min: 0.5  Med: 1.14 Max: 6.98
Current: 1.95
0.5
6.98
Earnings Yield (Greenblatt) (%) 2.00
HRT's Earnings Yield (Greenblatt) (%) is ranked higher than
59% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. HRT: 2.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HRT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.2  Med: 5.70 Max: 25.1
Current: 2
0.2
25.1
Forward Rate of Return (Yacktman) (%) -13.24
HRT's Forward Rate of Return (Yacktman) (%) is ranked lower than
87% of the 99 Companies
in the Global Medical Devices industry.

( Industry Median: 4.13 vs. HRT: -13.24 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
HRT' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -21  Med: -6.45 Max: 40.7
Current: -13.24
-21
40.7

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Arrhythmia Research Technology was incorporated under the laws of the State of Louisiana in 1981 and reincorporated under the laws of the State of Delaware in 1987. It completed an initial public offering in 1988. The Company through its wholly-owned subsidiary is a manufacturer specializing in plastic molding, precision metal and plastics machining and precious metal coating. It is also engaged in the development and licensing of signal averaged electrocardiography (SAECG) software, through its Predictor brand. The Company's technologies used in analyzing high resolution heart signals. Its Predictor software is used in research and clinical environments to diagnose the risk of certain heart arrhythmias. The Company invests in research and development, product support and sales efforts. The Company sells its services to its customers to provide product life cycle support to their product manufacturing needs. It provides complex value added US based manufacturing capabilities in injection molding, machining and plating/coating, mold making, maintenance and repair. The Company's operations are subject to government regulations which establish compliance standards and result in costs to comply in order to participate in certain markets.
» More Articles for HRT

Headlines

Articles On GuruFocus.com
Harte Gold Announces December 2014 Drill Results, 14.47 g/t Over 4.05m Resumes Exploration Drilling Jan 14 2015 
Harte Gold Announces Initial Closing Under Private Placement Dec 24 2014 
Harte Gold Discovers Hemlo Style Sericite Schist Shear Zone Along Contact Zone Nov 12 2014 
Harte Gold Reports More High Grade Results at Wolf Zone, 17.8g/t Gold Over 3.1 Meters Extends Wolf Z Oct 15 2014 
Longleaf Partners Believe HRT Could Be Their Most Exciting Investment Ever Jun 08 2011 
Arrhythmia Research Technology Inc Reports Operating Results (10-Q) Nov 10 2010 
Arrhythmia Research Technology Inc Reports Operating Results (10-Q) Aug 16 2010 
Arrhythmia Research Technology Inc Reports Operating Results (10-Q) May 04 2010 
Arrhythmia Research Technology Inc Reports Operating Results (10-Q) Oct 30 2009 
Arrhythmia Research Technology Inc (HRT) CFO David A Garrison buys 5,000 Shares Sep 17 2009 

More From Other Websites
ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ Files SEC form 8-K, Entry into a Material Definitive... Jun 23 2015
Arrhythmia Research Technology, Inc. Closes Two-Year Extension of Revolving Credit Facility Jun 23 2015
ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ Files SEC form 8-K, Other Events Jun 16 2015
Arrhythmia Research Technology, Inc. Adjourns Annual Meeting to July 1, 2015 Jun 16 2015
ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ Files SEC form 8-K, Regulation FD Disclosure, Financial... Jun 12 2015
ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ Financials May 22 2015
10-Q for Arrhythmia Research Technology, Inc. May 15 2015
ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ Files SEC form 8-K, Results of Operations and Financial... May 13 2015
Arrhythmia Research Technology, Inc. Reports First Quarter 2015 Results May 13 2015
10-K for Arrhythmia Research Technology, Inc. May 02 2015
ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ Files SEC form 8-K, Change in Directors or Principal... Apr 28 2015
Arrhythmia Research Technology, Inc. Appoints Robert A. Mello to Board of Directors Apr 28 2015
New Era Orthopaedics, LLC, to unveil new FDA-approved knee implants at the AAOS Annual Meeting -... Mar 23 2015
Micron Medical to Showcase New Brand, Contract Manufacturing Capabilities at World's Largest Meeting... Mar 23 2015
ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ Files SEC form 8-K, Results of Operations and Financial... Mar 20 2015
ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ Files SEC form 8-K/A, Change in Directors or Principal... Jan 23 2015
ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ Files SEC form 8-K, Change in Directors or Principal... Jan 12 2015
ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ Files SEC form 8-K, Regulation FD Disclosure, Financial... Dec 23 2014
Arrhythmia Research Tech (HRT) Upgraded From Sell to Hold Dec 04 2014
ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ Files SEC form 8-K, Results of Operations and Financial... Nov 12 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK